ACP3 and prostate carcinoma: One TAA, prostatic acid phosphatase (PAP), is the protein antigen overexpressed in prostatic cancer, that is the basis of one of the few therapeutic cancer vaccines approved for clinical use, Sipuleucel-T [13].